Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study

Hepatology

Volumn 52, Issue 6, 2010, Pages 1915-1921

  Piroth, Lionel ^a   Larsen, Christine ^b   Binquet, Christine ^a   Alric, Laurent ^c   Auperin, Isabelle ^d   Chaix, Marie Laure ^e   Dominguez, Stéphanie ^f   Duval, Xavier ^g   Gervais, Anne ^g   Ghosn, Jade ^h   Delarocque Astagneau, Elisabeth ^b,i   Pol, Stanislas ^j  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE VEILLE SANITAIRE   (France)

^c CHU PURPAN   (France)

^d Internal Medicine Department   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f Mondor Hospital   (France)

^g BICHAT HOSPITAL   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ INSTITUT PASTEUR   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALE HOMOSEXUAL; MULTICENTER STUDY; PREDICTIVE VALIDITY; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 78649613037     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23959     Document Type: Article

References (26)

1. Gambotti L, Batisse D, Colin-de-Verdiere N, Delaroque-Astagneau E, Desenclos JC, Dominguez S, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10: 115-117.
2. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197: 1558-1566.
3. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007; 14: 371-386.
4. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17: 201-207.
5. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
6. Fox J, Nastouli E, Thomson E, Muir D, McClure M, Weber J, et al. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS 2008; 22: 666-668.
7. Vogel M, Deterding K, Wiegand J, Gruner NH, Baumgarten A, Jung MC, et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009; 49: 317-319.
8. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48: 650-658.
9. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136: 1609-1617.
10. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20: 1157-1161.
11. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20: 233-240.
12. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12: 207-211.
13. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11: 1097-1101.
14. Vogel M, Page E, Matthews GV, Guiguet M, Dominguez S, Dore GJ, et al. The use of week 4 HCV-RNA after acute HCV infection (AHC) to predict chronic HCV infection. In: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA.
15. Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010; 15: 267-279.
16. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40: 41-46.
17. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-638.
18. De Rosa FG, Mollaretti O, Audagnotto S, De Blasi T, Cariti G, Marucco DM, et al. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. Clin Infect Dis 2009; 48: 1636-1637.
19. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41: 31-36.
20. McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200: 877-881.
21. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23-F29.
22. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14: 116-121.
23. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. HEPATOLOGY 2006; 43: 923-931.
24. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-333.
25. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. HEPATOLOGY 2006; 43: 250-256.
26. Low E, Vogel M, Rockstroh J, Nelson M. Acute hepatitis C in HIV-positive individuals. AIDS Rev 2008; 10: 245-253.